GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Ceftriaxone

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Rocephin / Ceftriaxone

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Ceftriaxone - product and source limitations

Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Ceftriaxone - product and source limitations

Official source

Ceftriaxone - labeled renal guidance

Renal action and limits

Ceftriaxone (Ceftriaxone), adult IV premixed solution
Renal impairment categories as defined by the cited product label

Action or finding
For renal impairment alone, doses up to 2 g/day generally need no adjustment. Hemodialysis removes little ceftriaxone.
Limits and monitoring
Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 26, posted May 21, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Ceftriaxone | GlobalRPh RX passage All evidence
Product / population
Ceftriaxone (Ceftriaxone), adult IV premixed solution
Renal measure
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 26, posted May 21, 2026
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Renal guidance: CLINICAL PHARMACOLOGY

For renal impairment alone, doses up to 2 g/day generally need no adjustment. Hemodialysis removes little ceftriaxone. Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.

Source revision: DailyMed SPL version 26, posted May 21, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Ceftriaxone - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 26, posted May 21, 2026

Renal measure: Renal impairment categories as defined by the cited product label

Read this dated source finding
Rxlist

Ceftriaxone - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Ceftriaxone - labeled renal guidance

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Ceftriaxone (Ceftriaxone), adult IV premixed solution

Renal method: Renal impairment categories as defined by the cited product label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Ceftriaxone - selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Ceftriaxone (Ceftriaxone), adult IV premixed solution

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Ceftriaxone - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Ceftriaxone - product and source limitations

Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.

How to use this: Apply only to the stated formulation, indication and renal population.

Ceftriaxone - labeled renal guidanceCeftriaxone - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Professional source

Stanford adult Ceftriaxone

Adult institutional dosing; not a manufacturer-label replacement.

Method: Not stated in selected source.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCeftriaxone - labeled renal guidanceCeftriaxone - selected RX renal passageStanford adult CeftriaxoneUCSF - ceftriaxone
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The gonorrhea regimen and dialysis comments are preserved historical GlobalRPh content, not a statement of current guideline recommendations.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/ceftriaxone/

Usual Dosing (Adults)

Adults: 1 to 2 grams daily, once daily or in two equal doses. For MSSA the source comments that 2 to 4 g/day may be required to achieve >90% target attainment. Maximum 4 g/day.

If chlamydial infection is suspected, add appropriate coverage because ceftriaxone has no activity against this organism. The historical source lists gonorrhea: 250 mg IM once. Surgical prophylaxis: 1 g IV 0.5 to 2 hours before surgery.

Continue therapy for at least 2 days after signs and symptoms have disappeared. Usual duration is 4 to 14 days; complicated infections may require longer. S. pyogenes infections require at least 10 days. No dose adjustment is necessary with renal or hepatic dysfunction alone.

GRPH-ceftriaxone-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

No renal adjustment; monitor blood levels in dialysis patients. In patients with both renal and hepatic dysfunction, dosage should not exceed 2 g/day.

GRPH-ceftriaxone-02 · Source section: Renal DosingRenal section finder

Hemodialysis

No specific manufacturer recommendations beyond blood-level monitoring; the source states dosage should not exceed 2 g/day. Peritoneal dialysis: 750 mg every 12 hours.

GRPH-ceftriaxone-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Ceftriaxone - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ceftriaxone (Ceftriaxone), adult IV premixed solution

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 26, posted May 21, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: CLINICAL PHARMACOLOGY

For renal impairment alone, doses up to 2 g/day generally need no adjustment. Hemodialysis removes little ceftriaxone. Concomitant significant renal and hepatic dysfunction requires separate review. Monitor for neurologic toxicity, particularly with severe impairment.

RDM74-ceftriaxone-official-1 · Source locator: Renal guidance: CLINICAL PHARMACOLOGY

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 26, posted May 21, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e95e1133abf6450f087c26f9bb3ad95cbb938a878d6aa01694d9c949146d604f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Ceftriaxone - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ceftriaxone (Ceftriaxone), adult IV premixed solution

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror limits its usual-dose statement to doses up to 2 g/day and reports little removal by hemodialysis.

RDM74-ceftriaxone-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ceftriaxone-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
93c35c63532738da01ec631fa9762105aa0eac70bf36001fd1aa082ba9c92304
Separate professional-source layer

University and professional protocols

Professional

Stanford adult Ceftriaxone

Open original reference

Open / share this exact local source

Stanford Antimicrobial Safety and Sustainability Program · Adult institutional dosing; not a manufacturer-label replacement.

Renal method: Not specified in this summary.
Source date: Antibiotic Subcommittee approved August 2026
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Source-specific regimen

Adult IV: usual 1-2 g daily; endovascular, osteomyelitis or PJI 2 g daily; meningitis or E. faecalis endocarditis 2 g every 12 hours. The table specifies no renal, HD or CRRT change.

ceftriaxone:stanford-ceftriaxone-1 · Source locator: PDF page 3, Ceftriaxone row

Source identity and provenance
Source
https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-ABX-Dosing-Guide.pdf
Retrieved
2026-09-05
Source date/version
Antibiotic Subcommittee approved August 2026
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
45cb208904dffa9eee53ddc70939dfd3651de0499f58be0262542afaaccfde4d
Professional

UCSF - ceftriaxone

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: No routine renal dose adjustment in the listed adult indications.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult IV regimens are not routinely reduced for kidney dysfunction or hemodialysis in this source. Standard treatment uses 2 g daily; UTI uses 1 g daily. Meningitis and enterococcal endocarditis treated with concomitant ampicillin use 2 g every 12 hours. Obesity (BMI >30) can warrant individualized higher dosing with ID/pharmacy input. The indication-specific regimen is retained rather than treating all renal patients as receiving one dose.

RDM30-012-ceftriaxone-1 · Source locator: UCSF - ceftriaxone; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftriaxone
Retrieved
2026-09-05
Renal-function method
No routine renal dose adjustment in the listed adult indications.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
260d56a9a4edd87b1c0433d53c1d2fd8a060bbcd37cf51329a55a07d6486e2cb

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ceftriaxone/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
f45ea5dd8930c1eb574fa71cb4e2b1c26b68db34a2c47b45d7f0d7f6507f9d8c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top